Abstract: The invention relates to a method of producing optically active ?-aminoaldehyde compound (3) by reacting imine compound (1-1) or sulfone compound (1-2) with aldehyde compound (2) in the presence of an optically active pyrrolidine compound. wherein each symbol is as defined in the specification.

Abstract: Disclosed are a process suited to large scale synthesis with high yield for producing oseltamivir phosphate, in which a preparation of oseltamivir phosphate which is highly safe as a pharmaceutical product can be produced, and an intermediate compound for producing oseltamivir phosphate. In this production process, an intermediate compound represented by general formula (V) is synthesized by employing Michael reaction/Michael reaction/Horner-Wadsworth-Emmons reaction, and oseltamivir phosphate is produced by converting the substituent groups in this intermediate compound.

Abstract: The present invention provides a production method of optically active 3-substituted-3-formyl-2-hydroxypropanoic acid compound (4), which includes a step of reacting glyoxylic acid compound (1-1) or (1-2) with aldehyde (2) in the presence of optically active pyrrolidine compound (3); wherein each symbol is as defined in the specification.

Abstract: An object of the present invention is to provide a therapeutic agent for accelerating recovery to accelerate a return to normal physical conditions by administering to an animal not in good health and under medical treatment, a treatment method, and the like. There is provided a therapeutic agent for accelerating recovery for animal use to accelerate the improvement of a physical condition of an animal under medical treatment which has a decreased activity (vigor) and is exhausted, which contains ghrelin or a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient and improves one or more of evaluation parameters consisting of activity (vigor), blood cell test values, biochemical test values, body temperature, the degree of anger or anxiety, and respiratory rate.

Abstract: Disclosed are a process suited to large scale synthesis with high yield for producing oseltamivir phosphate, in which a preparation of oseltamivir phosphate which is highly safe as a pharmaceutical product can be produced, and an intermediate compound for producing oseltamivir phosphate. In this production process, an intermediate compound represented by general formula (V) is synthesized by employing Michael reaction/Michael reaction/Horner-Wadsworth-Emmons reaction, and oseltamivir phosphate is produced by converting the substituent groups in this intermediate compound.

Abstract: The present invention provides a novel peptide having a physiological activity. Because of having a hypotensive activity, this novel peptide is useful in treating a disease caused by hypertension. Also, an antibody to the novel peptide is provided.

Abstract: The invention provides a spinal neuron damage treating agent for use in the treatment of spinal neuron damage, or an agent for promoting the proliferation of spinal neuronal precursor cells in the culture of spinal neuronal precursor cells, or an agent for promoting the regeneration of spinal nerves after transplantation of cultured spinal neuronal precursor cells, and the like. The invention provides an agent that contains a substance (e.g., ghrelin) that acts on the growth hormone secretagogue-receptor as an active ingredient, the agent being a spinal neuron damage treating agent for use in the treatment of spinal neuron damage, or an agent for promoting the proliferation of cultured spinal neuronal precursor cells in the culture of spinal neuronal precursor cells, or an agent for promoting the regeneration of spinal nerves after transplantation of cultured spinal neuronal precursor cells, and the like.

Abstract: The present invention provides a novel therapeutic agent for skin injuries and a skin regeneration accelerator. The therapeutic agent for skin injuries and the skin regeneration accelerator containing desacyl ghrelin or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: A compound represented by the general formula (I): (I) wherein R represents linear, branched, or cyclic alkyl or aryl; a process for producing the compound; and an antitumor agent containing the compound as an active ingredient.

Abstract: The present invention provides a novel therapeutic agent for skin injuries and a skin regeneration accelerator. The therapeutic agent for skin injuries and the skin regeneration accelerator containing a substance acting on a growth hormone secretagogue receptor or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The corresponding ?-aminooxy ketone is manufactured with a high yield and a high enantioselectivity. A manufacturing method for an optically active ?-aminooxy ketone derivative expressed by formula (1), wherein a ketone expressed by formula (2) is caused to react with a nitroso compound expressed by formula (3) in the presence of a proline derivative expressed by formula (4). In the formula, R1 and R2 respectively denote an alkyl, alkenyl or alkynyl group, and R1 and R2 may be linked to form a ring. R3 denotes an aryl, heterocyclic, alkyl, alkenyl or alkynyl group. A denotes a hydrogen atom, alkoxy group, aryloxy group, acyloxy group or silyloxy group which may have a substituent.

Abstract: The corresponding ?-aminooxy ketone is manufactured with a high yield and a high enantioselectivity. A manufacturing method for an optically active ?-aminooxy ketone derivative expressed by formula (1), wherein a ketone expressed by formula (2) is caused to react with a nitroso compound expressed by formula (3) in the presence of a proline derivative expressed by formula (4). In the formula, R1 and R2 respectively denote an alkyl, alkenyl or alkynyl group, and R1 and R2 may be linked to form a ring. R3 denotes an aryl, heterocyclic, alkyl, alkenyl or alkynyl group. A denotes a hydrogen atom, alkoxy group, aryloxy group, acyloxy group or silyloxy group which may have a substituent.

Abstract: A compound represented by the general formula (I): (I) wherein R represents linear, branched, or cyclic alkyl or aryl; a process for producing the compound; and an antitumor agent containing the compound as an active ingredient.

Abstract: There is provided a highly specific and highly sensitive assay method for platelet-activating factor (PAF). The invention may be employed to measure PAF levels in biological samples for elucidating the role of PAF in various pathological conditions. In addition, it is expected to facilitate diagnosis of various diseases associated with PAF fluctuation, and also contributing to evaluation of therapeutic effects on such diseases.

Abstract: In order to give a physician easy access to a patient placed in an interjacent space within a vertical magnet apparatus of a vertical magnet-type MRI apparatus, support and movement mechanisms 19 are provided on respective opposing surface sides of a pair of vertical opposing magnets 11, for supporting a cradle 22 or a seat 32 of a chair on belts 18, and moving the cradle 22 or the seat 32 in the horizontal direction by motors 17 and in the vertical direction by hydraulic cylinders 13.

Abstract: The present invention is directed to joint motion imaging and provides a vertical magnet type MRI system comprising a vertical magnet unit (10) having a pair of opposite vertical magnets (11), a movable table (20) provided with wheels (22) for traveling and a cradle (21) to carry a specimen laid down thereon, and capable of being moved into and moved out of a space between the pair of opposite vertical magnets (11), table locking devices (13) for locking the movable table (20) with the cradle (21) being in place between the pair of opposite vertical magnets (11), a movable chair (30) provided with wheels (32) for traveling and capable of being moved into and moved out of the space between the pair of opposite vertical magnets (11), and a chair locking device (14) for locking the movable chair (30) in place between the pair of opposite vertical magnets (11).

Abstract: In order to give a physician easy access to a patient placed in an interjacent space within a vertical magnet apparatus of a vertical magnet-type MRI apparatus, support and movement mechanisms 19 are provided on respective opposing surface sides of a pair of vertical opposing magnets 11, for supporting a cradle 22 or a seat 32 of a chair on belts 18, and moving the cradle 22 or the seat 32 in the horizontal direction by motors 17 and in the vertical direction by hydraulic cylinders 13.

Abstract: The present invention is directed to joint motion imaging and provides a vertical magnet type MRI system comprising a vertical magnet unit (10) having a pair of opposite vertical magnets (11), a movable table (20) provided with wheels (22) for traveling and a cradle (21) to carry a specimen laid down thereon, and capable of being moved into and moved out of a space between the pair of opposite vertical magnets (11), table locking devices (13) for locking the movable table (20) with the cradle (21) being in place between the pair of opposite vertical magnets (11), a movable chair (30) provided with wheels (32) for traveling and capable of being moved into and moved out of the space between the pair of opposite vertical magnets (11), and a chair locking device (14) for locking the movable chair (30) in place between the pair of opposite vertical magnets (11).

Abstract: In order not to nip the clothes or skin of a subject between the joining portions of coil members when a detecting coil for a magnetic resonance diagnostic apparatus is fitted around a region of the subject such as the leg or neck, the detecting coil 100 for a magnetic resonance diagnostic apparatus, which can be separated into an upper coil member 10 and a lower coil member 20 and has an annular shape when these members 10, 20 are integrally joined, is provided at the joining portions of the lower coil member 20 with guards 27, 28 of a silicone rubber having a hardness of Hs80.

Abstract: A compound represented by the general formula (I): (I) wherein R represents linear, branched, or cyclic alkyl or aryl; a process for producing the compound; and an antitumor agent containing the compound as an active ingredient.